Patent Application
20080275014
Seborrheic dermatitis (SD) is a common inflammation of the skin, generally occurring on the face, scalp and chest. See Gupta A K, et al., J. Eur Acad Dermatol Venereol 2004; 18(1):13-26; and Kligman A M, et al., J. Cosmetic Chemists 1976; 27:111-39. Symptoms of the disease include hyperseborrhae, dandruff, erythema, and itching. In some patients, flexural areas may also be involved. The exact role of malassezia yeasts including Malassezia furfur, formerly Pityrosporum ovale in SD pathophysiology (an abnormal host response and an inflammatory response to toxins) remains unclear. See Bergbrant I M, et al., Acta Derm Venereol 1989; 69:332-335; and Parry M E, Sharpe G R. Seborrheic dermatitis is not caused by an altered immune response to Malassezia yeast. (Br J. Dermatol 1998; 139:254-63).
Known for their excellent efficacy and anti-inflammatory profile, corticosteroids have been used for many years to treat SD. However, due to safety concerns they are being more and more replaced by antifungals such as ketoconazole. In addition, some studies demonstrated that ketoconazole was at least as effective as hydrocortisone 1% cream in the global reduction of symptoms when applied once daily. See Peter R U, et al., Br J. Dermatol 1995; 132:441-5; and Stratigos JD et al., J. Am. Acad. Dermatol 1988; 19: 850-3. A shampoo comprising clobetasol has already been described for the treatment of psoriasis in WO 99/65456.
Accordingly, there is a need to develop an effective and safe method of treating SD using a corticosteroid.
The present invention features an effective and safe treatment of seborrheic dermatitis by the application of a corticosteroid, clobetasol propionate, onto the scalp of human subjects afflicted with seborrheic dermatitis.
Specifically, the present regime or regimen is effective and safe compared with the use of ketoconazole 2% foam, and a placebo containing no active, in subjects afflicted with seborrheic dermatitis.
Accordingly, the present invention is directed to the use of an effective amount of corticosteroid for the preparation of a shampoo intended for the treatment of seborrheic dermatitis of the scalp. Preferably, the corticosteroid is clobetasol propionate.
The present invention is also directed to a regime or regimen for treating a human suffering from seborrheic dermatitis, comprising the steps of:
The corticosteroid may be chosen amongst alclometasone dipropionate amcinonide, beclomethasone dipropionate, betamethasone benzoate, betamethasone dipropionate, betamethasone valerate, budesonide, clobetasol propionate, in particular, clobetasol 17-propionate, clobetasol butyrate, desonide, desoximetasone, dexamethasone, diflorasone diacetate, diflucortolone valerate, flurandrenolone, fluprednidene acetate, fluocortolone, fluocortine butyl, fluocinonide, fluocinolone acetonide, fluclorolone acetonide, flumetasone pyvalate, feudiline chlorhydrate, flumetholone, halcinonide, hydrocortisone, hydrocortisone acetate, hydrocortisone butyrate, hydrocortisone valerate, methylprednisolone acetate, mometasone furoate, methylprednisolone, prednisolone, triamcinolone acetonide, especially betamethasone salts and clobetasol propionate.
This period of time after the application of the shampoo and before the rinsing off of the shampoo from the scalp may preferably be about two and half minutes, five minutes, ten minutes or 15 minutes.
The concentration of clobetasol propionate is preferably comprised between 0.02% and 1%, and more preferably of about 0.05% of the shampoo. The shampoo may further comprise at least one surfactant and/or an alcohol. The shampoo may preferably comprise at least one of the following compounds: alcohol, coco-betaine, sodium laureth sulfate, polyquaternium, and citric acid or salt thereof.
Multicentre randomized, investigator-blind, vehicle- and active-controlled, parallel group study.
Male or female subjects aged from 18 to 70 years afflicted with scalp SD, defined as a total severity score (TSS, sum of erythema, loose and adherent desquamation) of at least 2;
Subjects using topical or systemic anti-SD therapies were to respect treatment specific washout periods.
Subjects were randomized to receive either:
All subjects were asked to rinse off treatment after specified application time. Products were applied twice weekly for 4 weeks.
Specifically, the 0.05% clobetasol propionate shampoo that was used in the study has the formulation described in Table 2.
Score assessments at each visit included: desquamation (loose and adherent) and erythema on each quarter of the scalp. Signs were evaluated at each visit using a seven-point scale from 0 to 3, with half points being allowed;
TSS and a mean score for each sign were calculated for the whole scalp; Other criteria were itching, as assessed at each visit by the subject on a 100 mm analogue scale and global improvement, as assessed by the investigator on a seven-point scale (from −1: worse than baseline to 5: clear) at each visit following baseline.
Overall safety was assessed throughout based on adverse event reporting.
A total of 55 subjects (11 in each treatment group) were randomized into the study;
Four subjects withdrew from the study: one in the clobetasol propionate 10 minute group, 1 in clobetasol 5 minute, both for administrational reasons, and 2 in the clobetasol vehicle group (1 upon subject's request and one other due to lack of efficacy);
54.5% were male and 45.5% were female. The proportion of male and female subjects was similar in each treatment group except in the clobetasol 10 minute group which comprised more than 80% males;
All treatment groups were comparable in terms of race, and age (Table 1).
At end point there was a statistically significant difference (all p≦0.02) for the mean TSS between the active treatments groups (0.7; 0.6; 0.8; 0.7 for clobetasol propionate 10 minute, 5 minute, 2.5 minute and ketoconazole, respectively) and the clobetasol vehicle group (2.6).
At endpoint mean percent changes for the TSS from baseline ranged from 75.6% for the 2.5 minute application to 82.3% for the 5 minute application of clobetasol and reached 76.9% for ketoconazole and 17.4% for the vehicle (
Differences for mean erythema scores between the vehicle (0.7) and the active treatments were statistically significant for clobetasol propionate 5 minute (0.1; p=0.024) and ketoconazole (0.1; p=0.027).
For loose desquamation the difference to the vehicle (1.0) was statistically significant for clobetasol propionate 10 minute (0.3; p=0.027). A trend to significance could be observed for clobetasol 5 minute (0.4; p=0.051). It is of importance to note that no statistical difference could be found between ketoconazole and the vehicle on this criterion.
For adherent desquamation a statistically significant difference to the vehicle (0.9) could be shown for clobetasol propionate 5 minute (0.1; p=0.047). At end point, the mean score of itching (as expressed in mm) had decreased from baseline in all treatment groups. The difference between the vehicle score (34) and the active treatments scores was statistically significant for clobetasol propionate 5 minute achieving a score of 4.8 (p=0.007),
The percentage of subjects with at least marked global improvement at the end point was higher in the active treatment groups (63.7%, 81.9%, 45.5% in the clobetasol propionate 10, 5, and 2.5 minute groups, respectively, and 72.8% in the ketoconazole group) than in the clobetasol propionate vehicle group (27.3%),
Clearance of SD was achieved in 45.5% of clobetasol 10 minute-treated subjects, this percentage was higher than with the other active treatments and the vehicle 9.1% for ketoconazole and the vehicle, 18.2% for clobetasol propionate 5 and 2.5 minutes). The difference between the clobetasol vehicle and the 4 active treatments was statistically significant (p-values≦0.05).
Accordingly, despite recent investigations suggesting that Malassezia is the causal organism of the disease and that an anti-fungal treatment is the most appropriate treatment, the present invention provides a safe and effective method of treating seborrheic dermatitis of the scalp comprising a short contact application to the scalp of a clobetasol propionate containing shampoo.
This study was conducted as a single center, randomized, investigator-masked and competitor comparison of 4 parallel groups involving Psoriasis and Scalp seborrheic dermatitis subjects. The aim of the trial was to evaluate the opthalmological irritation potential and the potential to suppress the HPA axis of Clobetasol Propionate Shampoo, 0.05%. During 4 weeks, psoriasis subjects had to treat their scalp once a day with Clobetasol Shampoo, 0.05% or with Dermoval/Temovate gel. Scalp seborrheic dermatitis subjects had to treat their scalp twice a week with Clobetasol Shampoo, 0.05% or on a day with Dermoval/Temovate gel.
Each subjects was submitted at each visit (each week during 4 weeks) to the following tests, ocular examination, HPA-axis function, local and general safety. First, opthalmological examination, measurement of intraocular pressure, detection of ocular subjective symptoms such as burning sensation, measurement of far and near visual acuity. Second, they were sampled for serum cortisol levels and were submitted to the Cosyntropin (Synacthene) stimulation assay. Cutaneous safety (skin atrophy using B-Scan ultra-sound and telangiectasis) and adverse events were also recorded. Systemic safety was also assessed by routine laboratory test and detection of Clobetasol Plasma levels, cutaneous safety, and DSS at the end of the study.
Fifty two subject aged from 18 to 56 years were enrolled in the study and four subjects discontinued (i.e. one subject's request and three discontinuations due to adverse events unrelated to study products).
Considering ophtalmological examination, no change in the slip lamp examination as regard corneal and conjonctival signs as well as intraocular pressure was observed.
None of the subjects who applied Clobetasol propionate shampoo 0.05% experienced HPA Axis suppression neither in scalp seborrheic dermatitis group nor in scalp psoriasis group. The same observation was made for the subjects who applied Dermoval/Temovate gel in both diseases groups. However, few subjects presented at least once during the study either a pre-stimulation cortisol level below 10 μg/dl or a post-stimulation increase of cortisol level below 8 μg/dl. None of them were considered as showing HPA axis suppression as both conditions were not observed at the same time.
Concerning the secondary criteria for evaluation, the ocular subjective evaluation did not reveal any burning or stinging reactions for all the subjects. The cutaneous safety examination was very good for both tested products. No clinically relevant changes in visual acuity were observed for any subjects along the study and no treatment effect on visual acuity was suspected. Thus, the ocular tolerance for Clobetasol propionate shampoo 0.05% and for Dermoval/Temovate gel was excellent along the study for all the subjects. No detectable amounts of Clobatasol 17-propionate were found in any of the 45 subject plasma samples analyzed.
No clinically significant changes were found in the laboratory test values (i.e. hematology, blood chemistry and urinalysis) from baseline to end of study for all the subjects included in the study.
Under the conditions of study, Clobetasol propionate shampoo 0.05% did not show any opthalmological irritant potential or the ability to suppress the HPA Axis Function for any subjects either with scalp seborrheic dermatitis or scalp psoriasis. The overall ocular, cutaneous and tolerance was good along the study.
There were no cases of HPA axis suppression, telangiectasia or skin atrophy reported during the course of the study.
The aim of this study was to compare the in vitro liberation-penetration of clobetasol 17-propionate from Clobex shampoo to the one of a 0.05% (w/w) commercial formulation (Temovate Scalp Application) under the same application conditions (after 16 hours of topical application). The skin was maintained in static diffusion cells. The formulations were applied on human skin under non-occluded conditions.
The two formulations containing clobetasol 17-propionate were:
A: Clobex shampoo containing 0.05% (w/w) of clobetasol 17-propionate
B: Temovate Scalp Application containing 0.05% (w/w) of clobetasol 17-propionate
Six skin samples from different female donors were used to compare the two formulations (two application times for the shampoo) for a total of 12 cells per formulation. A target dose of 10 mg of formulation (5 micrograms of clobetasol 17-propionate) was applied to a skin surface of 1 cm2 per cell.
Concerning Clobex shampoo, the percutancous penetration of clobetasol 17-propionate was evaluated with and without washing of the skin surface with tap water (usual condition of application) after 15 minutes of topical application. The skin samples were maintained in static diffusion cells during 16 hours. The formulations were applied on human skin under non-occluded conditions. The application schedule was performed according to a design including effects of experiment (which corresponds to skin origin), cell (which corresponds to skin thickness) and formulation. Concentrations of clobetasol 17-propionate were measured using an HPLC-APCL-MS method. The limit of quantification was 5 ng of clobetasol 17-propionate per mL of sample.
Concerning the in vitro comparison of Clobex shampoo to a 0.05% (w/w) commercial formulation (Temovate Scalp Application) in the same application conditions (after 16 hours of topical application), the experimental results showed: the total cutaneous penetration (epidermis and dermis) varied from 0.32⊥0.05 μg (7% of the applied dose, Temovate Scalp application) to 0.81⊥0.25 μg (19% of the applied dose Clobex shampoo) after 16 hours of application.
Each patent, patent application, publication and literature article/report cited or indicated herein is hereby expressly incorporated by reference. While the invention has been described in terms of various specific and preferred embodiments, the skilled artisan will appreciate that various modifications, substitutions, omissions, and changes may be made without departing from the spirit thereof. Accordingly, it is intended that the scope of the present invention be limited solely by the scope of the following claims, including equivalents thereof.
1The formulation identification code number 662.066 is a GALDERMA Laboratories development code. This formulation ID code appears in other documents and sections comprising this application and is considered as the principal ID code for the formulation.
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/EP2005/014230 | 12/8/2005 | WO | 00 | 1/17/2008 |
| Number | Date | Country | |
|---|---|---|---|
| 60634105 | Dec 2004 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 11017665 | Dec 2004 | US |
| Child | 11792143 | US |
